Citadel Advisors’s CASI Pharmaceuticals CASI Stock Holding History

Citadel Advisors’s Portfolio CASI Stock Details CASI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-400	Closed	-$2.38K	–	14570
2024 Q3	$2.38K	Buy	+400	New	+$2.59K	﹤0.01%	13754
2024 Q1	–	Sell	-2,300	Closed	-$16.7K	–	14611
2023 Q4	$16.7K	Buy	+2,300	New	+$11.1K	﹤0.01%	12778

Other funds holding CASI

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Citadel Advisors's CASI Position: Q1 2026 in Review

Citadel Advisors sold out of CASI Pharmaceuticals (CASI) in Q1 2026, closing a stake of 14,045 shares — an estimated $11.9K sold.

Citadel Advisors first reported a position in CASI in Q1 2014 and held it in 20 quarters. The position peaked at $255K in Q4 2019. 1 fund tracked by Wall St. Rank holds CASI as of Q1 2026.

Citadel Advisors reported no remaining CASI Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Citadel Advisors sold 14,045 CASI Pharmaceuticals shares in Q1 2026, an estimated $11.9K.
Citadel Advisors first reported a position in CASI Pharmaceuticals in Q1 2014 and held it in 20 quarters.
Citadel Advisors's CASI Pharmaceuticals position peaked at $255K in Q4 2019.
1 fund tracked by Wall St. Rank held CASI Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.